Selenopeptides — hybrid molecules combining selenium's redox properties with peptide tumor-targeting — show anticancer activity through multiple pathways including immune activation, apoptosis induction, and angiogenesis inhibition.
4 anticancer mechanismsSelenopeptides fight cancer through PI3K/Akt modulation, immune cell activation, angiogenesis inhibition, and apoptosis induction — making resistance harder to develop
What the researchers found
The review identifies selenopeptides as a new class of anticancer agents with several key features:
Sources and synthesis: Selenopeptides can be derived from selenium-rich foods through enzymatic hydrolysis, or synthesized via solid-phase and liquid-phase peptide synthesis
Multiple anticancer mechanisms:
- Modulation of the PI3K/Akt signaling pathway (a master regulator of cell growth and survival)
- Activation of immune cells to attack tumors
- Inhibition of angiogenesis (blocking new blood vessel formation that tumors need to grow)
- Induction of cancer cell apoptosis (programmed cell death)
Evidence from in vitro, in vivo, and preliminary clinical studies confirms selenopeptides can inhibit cancer cell proliferation and reduce tumor markers.
Why it matters
Selenium is an essential trace element with well-documented anticancer properties at appropriate doses, but selenium compounds often lack specificity and can be toxic at higher concentrations. By incorporating selenium into peptide structures, selenopeptides potentially achieve targeted delivery to tumor cells while preserving selenium's anticancer redox activity. The multitarget mechanism is particularly attractive because it makes it harder for cancer cells to develop resistance through a single mutation.
How the study worked
This is a comprehensive review article synthesizing recent literature on selenopeptide anticancer research. It covers sources, preparation methods, mechanisms of action, and evidence from preclinical and preliminary clinical studies.
What this study cannot tell us
As a review, this paper does not present original data. The 'preliminary clinical studies' mentioned are not detailed in the abstract — the level of clinical evidence is unclear. Selenopeptides are a heterogeneous class with widely varying structures, and results from one selenopeptide may not apply to others. Selenium toxicity is a real concern at higher doses, and the therapeutic window for selenopeptides needs careful definition. Most evidence appears to be preclinical, and clinical translation faces significant challenges including standardization of food-derived selenopeptides.
How to read the evidence
This is a review article summarizing mostly preclinical evidence (in vitro and in vivo studies) with mention of preliminary clinical data. The field is early-stage, and the evidence for clinical anticancer efficacy of selenopeptides is not yet established through rigorous clinical trials.
When this study was published
Published in 2026, this review captures the current state of a rapidly developing field. Selenopeptide research is still primarily preclinical, with clinical translation in early stages.
The bigger picture
Selenopeptides sit at the intersection of two active research areas: selenium-based anticancer therapy and peptide-based drug delivery. As the field of peptide therapeutics expands beyond hormones and signaling molecules into oncology, incorporating trace elements like selenium adds a new dimension — combining the targeting precision of peptides with the broad anticancer properties of inorganic elements. This approach could lead to food-derived anticancer supplements or precision therapeutics depending on the development path.
Questions still open
- What is the optimal selenium-to-peptide ratio for maximizing anticancer activity while minimizing selenium toxicity?
- Can food-derived selenopeptides be standardized enough for clinical use, or will synthetic approaches be necessary?
- How do selenopeptides compare in efficacy and safety to existing selenium supplements and conventional chemotherapy in clinical settings?
Common questions
What are selenopeptides and how are they different from regular selenium supplements?
Can you get selenopeptides from food?
Read the original research
Anticancer selenopeptides from food sources: synthesis strategies and multitarget mechanisms.
iScience, 29(3), 114895
Citation
Ma, Mingyu; Zhou, Xiaotong; Qiao, Xinyue; Li, Linling; Cheng, Shuiyuan; Lu, Yingtang; Cheng, Hua. (2026). Anticancer selenopeptides from food sources: synthesis strategies and multitarget mechanisms.. iScience, 29(3), 114895. https://doi.org/10.1016/j.isci.2026.114895